Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

Associate

Andrea Akinbola

Goodwin Procter

main

Akinbola Andrea

Goodwin Law Clerk Andrea Akinbola, from Boston, practices in Business Law.

Andrea Akinbola

Areas of Practice

Professional Activities

PROFESSIONAL EXPERIENCE

Credentials

Education

JD

BA

Admissions

Bars

Related Content

AlloVir and Kalaris Therapeutics to Merge

SciAps To Be Acquired By Spectris For Up To $260 Million

Human Immunology Biosciences to be Acquired by Biogen For $1.15 Billion Upfront and up to $650 Million in Potential Milestone Payments

Goodwin’s REITs Capital Markets Team Advises Underwriters on American Healthcare REIT’s $772.8 Million Initial Public Offering, the Largest REIT IPO in Six Years

Novo Holdings to Acquire Catalent in All-Cash $16.5 Billion Transaction

Q32 Bio and Homology Medicines To Merge

Goodwin Advises Thoma Bravo on $1.8 Billion Acquisition of NextGen Healthcare, Inc.

Orchard Therapeutics To Be Acquired By Kyowa Kirin For $387 Million and Contingent Value Rights

Mergers & Acquisitions